HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Hedges, J. R. Search for Related Content PubMed PubMed Citation Articles by Hedges, J. R. Related Collections Laboratory Management Evidence Based Laboratory Medicine and Test Utilization Proteomics and Protein Markers

Cardiac Enzyme Availability and Hospital Length of Stay

Department of Emergency Medicine, School of Medicine, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd., UHN-52, Portland, OR 97201-3098, Fax 503-494-7689, E-mail Hedgesj@ohsu.edu

In this issue of Clinical Chemistry, Wu and Clive report an association between hospital length of stay (LOS) and the potential availability of CK-MB results (i.e., anticipated turnaround times, given the institutional approach to measurement) at acute-care hospitals in Massachusetts (1). They report a 0.7-day reduction in mean hospital LOS for those patients with an acute myocardial infarction (AMI) and complication(s) who were managed at hospitals performing CK-MB tests more than once or twice per day. They comment that if this reduction in LOS is real, the small increase in institutional cost to provide more-rapid enzyme results would be more than offset by savings related to the shorter hospital LOS.

To put this study into context, one must address several issues: What methodological issues might bias these study results? How are LOS values shortened by the more rapid turnaround times for cardiac enzymes? And why weren't shorter LOSs seen in other DRG categories?

What methodological issues might bias this study? This retrospective observational study design used a claims-based database. Such a billing database may insufficiently permit patient risk stratification for hospital LOS. For example, from such a database alone, we know nothing of patients' socioeconomic status and little about their underlying health status. Both factors may significantly affect clinical disposition decisions. Further, the analysis performed did not address the impact of other factors such as infarct location or procedural interventions (e.g., angioplasty or thrombolysis) on hospital LOS.

There also is significant potential for selection bias at . . . [Full Text of this Article]

References

The following articles in journals at HighWire Press have cited this article:

				R. H. Christenson, F. S. Apple, D. L. Morgan, G. L. Alonsozana, K. Mascotti, M. Olson, R. T. McCormack, F. H. Wians Jr., J. H. Keffer, and S.-H. Duh Cardiac troponin I measurement with the ACCESS® immunoassay system: analytical and clinical performance characteristics Clin. Chem., January 1, 1998; 44(1): 52 - 60. [Abstract] [Full Text] [PDF]